<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Int Braz J Urol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Int Braz J Urol</journal-id>
      <journal-title-group>
        <journal-title>International Brazilian Journal of Urology : official journal of the Brazilian Society of Urology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1677-5538</issn>
      <issn pub-type="epub">1677-6119</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Urologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26005986</article-id>
      <article-id pub-id-type="pmc">4752108</article-id>
      <article-id pub-id-type="publisher-id">S1677-5538.IBJU.2015.02.31</article-id>
      <article-id pub-id-type="doi">10.1590/S1677-5538.IBJU.2015.02.31</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Radiology Page</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>18F-FDG PET/CT with unusual bone and CNS metastases from testicular seminoma</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>G&#xF3;mez</surname>
            <given-names>Francisco Javier Garc&#xED;a</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>B&#xE1;&#xF1;ez</surname>
            <given-names>Irene Acevedo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gonz&#xE1;lez</surname>
            <given-names>Roberto Lasso Vega</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jim&#xE9;nez-Granero</surname>
            <given-names>Pedro</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dorado</surname>
            <given-names>Isabel Borrego</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Department of Nuclear Medicine,Virgen del Roc&#xED;o Univesitary Hospital, Seville, Spain and</aff>
      <aff id="aff2"><label>2</label>Department of Medical Oncology. Virgen del Rocio Universitary Hospital. Seville, Spain</aff>
      <author-notes>
        <corresp><bold>Correspondence address: </bold>Francisco Javier Garc&#xED;a G&#xF3;mez, MD. Department of Nuclear Medicine. Virgen del Roc&#xED;o Universitary Hospital. 41013, Seville, Spain. Telephone: +34 6 8092-5869. E-mail: <email>javier191185@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Mar-Apr</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Mar-Apr</season>
        <year>2015</year>
      </pub-date>
      <volume>41</volume>
      <issue>2</issue>
      <fpage>393</fpage>
      <lpage>394</lpage>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>7</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>10</day>
          <month>12</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <counts>
        <fig-count count="1"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="3"/>
        <page-count count="2"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <p>A 31 year old male with a previous history of testicular seminoma with complete reponse after orchiectomy and three cycles of BEP scheme, was referred for 18F-FDG PET/CT with a standard procedure for progressive decline consistent in spinal pain, gait difficulty and Charcot&#x2019;s neurologic triad (scanning speech, intention tremor and nystagmus) initiated eight month after third course of chemotherapy. Dorsal spine MRI revealed a space-occupying lesion at left T6 lamina. Histology examination confirmed a seminoma metastatic to spine.</p>
    <p>A wholebody and cerebral 18F-FDG PET/CT scan was performed 60 minutes after intravenous injection of 370 MBq of 18F-FDG. PET/CT scan demonstrated an augmentation of soft tissue due laminectomy with increased uptake of radiotracer and a Standardized Uptake Value (SUV) maximum of 4.84 (<xref ref-type="fig" rid="f01">Figure-1</xref>, Panel a), so persistence of tumour tissue cannot be excluded. Furthermore, two focal hypermetabolic areas in CNS were revealed. First, located in the spinal cord at C4-C5 vertebral levels with a SUV maximum of 7.49 (<xref ref-type="fig" rid="f01">Figure-1</xref>, Panel b) and second, in the cerebellum with a SUV maximum of 11 (<xref ref-type="fig" rid="f01">Figure-1</xref>, Panel c), corresponding with 3.9 cm mass in vermix observed at post-hoc MRI scan.</p>
    <p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Wholebody and cerebral 18F-FDG PET/CT scan after i.v. administration of 370 MBq of 18F-FDG. Panel a) Axial images that revealed an augmentation of soft tissue due left T6 laminectomy with increased uptake of radiotracer and SUV maximum of 4.84 that cannot allow to excluded the persistence of tumour tissue. Panel b) Sagital images showed a spinal cord metastasis with increased uptake of radiotracer at C4-C5 vertebral levels with a SUV maximum of 7.49. Panel c) Cerebral scan revealed a hypermetabolic mass in cerebellum, with high uptake of 18F-FDG (SUV maximum of 11), corresponding with 3.9 cm mass in vermix observed at post-hoc MRI scan.</title></caption><graphic xlink:href="1677-5538-ibju-41-2-0393-gf01"/></fig>
</p>
    <p>This is an unusual intra-extracranial metastatic tumor merits active treatment.</p>
    <p>Most relapses of seminoma occur within the first 3 years after orchiectomy. Bone and CNS metastases involvement are an extremely rare event. A report of 2,550 patients revealed bone metastases only in 3 patients with seminoma (0.12%) (<xref rid="B1" ref-type="bibr">1</xref>). Moreover, CNS occurred only once in a series of 142 patients (0.7%) (<xref rid="B2" ref-type="bibr">2</xref>). Higher uptake in seminomas than in nonseminomas testicular carcinomas (<xref rid="B3" ref-type="bibr">3</xref>) makes 18F-FDG PET/CT a powerful tool in evaluating postchemotherapy seminoma relapses.</p>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jamal-Hanjani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Karpathakis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kwan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mazhar</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ansell</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Shamash</surname>
              <given-names>J</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Bone metastases in germ cell tumours: lessons learnt from a large retrospective study</article-title>
          <source>BJU Int</source>
          <year>2013</year>
          <volume>112</volume>
          <fpage>176</fpage>
          <lpage>181</lpage>
          <pub-id pub-id-type="pmid">23795785</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mencel</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Motzer</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Mazumdar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vlamis</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Bajorin</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Bosl</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients</article-title>
          <source>J Clin Oncol</source>
          <year>1994</year>
          <volume>12</volume>
          <fpage>120</fpage>
          <lpage>126</lpage>
          <pub-id pub-id-type="pmid">7505805</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cremerius</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Effert</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Adam</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sabri</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Zimmy</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wagenknecht</surname>
              <given-names>G</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>FDG PET for detection and therapy control of metastatic germ cell tumor</article-title>
          <source>J Nucl Med</source>
          <year>1998</year>
          <volume>39</volume>
          <fpage>815</fpage>
          <lpage>822</lpage>
          <pub-id pub-id-type="pmid">9591582</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
